Combination omalizumab and mepolizumab therapy for refractory allergic bronchopulmonary aspergillosis

J Allergy Clin Immunol Pract. 2017 Jul-Aug;5(4):1137-1139. doi: 10.1016/j.jaip.2017.01.013. Epub 2017 Mar 6.

Authors

Matthew C Altman¹, Jake Lenington², Steve Bronson², Andrew G Ayars³

Affiliations

¹ University of Washington Medical Center, Seattle, Wash; Center for Allergy and Inflammation, UW Medicine at South Lake Union, Seattle, Wash. Electronic address: maltman@uw.edu.
² University of Washington Medical Center, Seattle, Wash.
³ University of Washington Medical Center, Seattle, Wash; Center for Allergy and Inflammation, UW Medicine at South Lake Union, Seattle, Wash.

PMID: 28279664
DOI: 10.1016/j.jaip.2017.01.013

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adrenal Cortex Hormones / therapeutic use
Anti-Allergic Agents / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
Antifungal Agents / therapeutic use
Aspergillosis, Allergic Bronchopulmonary / diagnosis
Aspergillosis, Allergic Bronchopulmonary / drug therapy*
Aspergillus fumigatus / immunology*
Drug Resistance
Drug Therapy, Combination
Female
Humans
Hypersensitivity / diagnosis
Hypersensitivity / drug therapy*
Middle Aged
Omalizumab / therapeutic use*
Recurrence
Respiratory Insufficiency

Substances

Adrenal Cortex Hormones
Anti-Allergic Agents
Antibodies, Monoclonal, Humanized
Antifungal Agents
Omalizumab
mepolizumab